Actavis Completes Forest Laboratories Acquisition LEARN MORE>
Actavis Completes Forest Laboratories Acquisition

Research & Development

Fueling R&D with ~$1.7 Billion Investment

Allergan’s strategically focused R&D engine is built on novel compounds in specialty and primary care markets where there is significant unmet medical need, and fueled by an investment of approximately $1.7 billion in 2015. With an innovative product development portfolio exceeding 20 near-term projects and a world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. and more than 1,000 marketing authorizations globally, we are uniquely positioned within our industry to ensure our development activities support sustainable long-term organic growth.